PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

About this update from Pharmather Holdings Ltd

Anticipated peptide reclassification could expand the addressable market for PharmaTher's PharmaPatch™ product strategy and PatchPrint™ manufacturing platform, strengthening its position in next-generation peptide deliveryToronto, Ontario--(Newsfile Corp. - April 16, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies and peptide-enabled product opportunities, today expressed support for recent U.S. initiatives led by U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and the U.S. Food and Drug Administration (FDA) to revisit the regulatory treatment of select therapeutic peptides."We applaud Secretary Kennedy and the FDA for advancing a science-based, patient-centered review of the peptide compounding framework and for supporting a more practical, medically supervised pathway for selected therapeutic peptides," said Fabio Chianelli, Chief Executive Officer of PharmaTher. "We believe this evolving policy direction could be highly value-accretive for PharmaTher, as it directly aligns with the peptide-focused strategy we have built around PharmaPatch™ and PatchPrint™. A clearer and more accessible regulatory path for peptides would be constructive for patients, prescribers and innovators, while strengthening the commercial relevance of our peptide delivery, formulation and manufacturing capabilities. As the regulatory landscape evolves, we believe PharmaTher is strategically ahead of the shift and well positioned to expand its peptide-focused opportunities."PharmaTher believes the current U.S. policy review, including the FDA's planned July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee and related public comment process, could represent an important catalyst for the Company's peptide-focused strategy. According to the FDA's notice, the Committee is scheduled to review BPC-157-related, KPV-related, TB-500-related and MOTs-C-related bulk drug substances on July 23 for possible inclusion on the Section 503A Bulks List. PharmaTher believes this is directly relevant to its previously announced peptide strategy, as BPC-157, KPV and TB-500 are already among the peptide candidates it has identified for evaluation under PharmaPatch™. If the regulatory pathway for certain peptides becomes more accessible, the Company b...

View stock analysis, news, and events for Pharmather Holdings Ltd